ArticleACS central science2019
Design of Safe Nanotherapeutics for the Excretion of Excess Systemic Toxic Iron.
Article in ACS central science, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 40 citations in OpenAlex.
- Trial
- A dual-pronged strategy: multi-bioactive nanoplatform synergizes ROS antidote and iron stabilization to protect against liver ischemia-reperfusion injury.Journal of nanobiotechnology · 2026Article
- Comparative evaluation of microfluidic-synthesized nano-niosomes versus liposomal and micro-niosomal deferoxamine in murine iron overload models.Research in pharmaceutical sciences · 2026Article
- Aging at the Crossroads of Cuproptosis and Ferroptosis: From Molecular Pathways to Age-Related Pathologies and Therapeutic Perspectives.International journal of molecular sciences · 2026Review
- Exploring the potential of repurposed deferoxamine: bridging challenges and novel formulation opportunities.Nanomedicine (London, England) · 2025Review
- Intranasal delivery of iron chelators and management of central nervous system disease.Frontiers in pharmacology · 2025Review
- Hub genes, a diagnostic model, and immune infiltration based on ferroptosis-linked genes in schizophrenia.IBRO neuroscience reports · 2024Article
- A Dual-Kinetic Control Strategy for Designing Nano-Metamaterials: Novel Class of Metamaterials with Both Characteristic and Whole Sizes of Nanoscale.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
- Current insights into the functional roles of ferroptosis in musculoskeletal diseases and therapeutic implications.Frontiers in cell and developmental biology · 2023Review
- Iron metabolism in colorectal cancer.Frontiers in oncology · 2023Review
- Synergetic delivery of artesunate and isosorbide 5-mononitrate with reduction-sensitive polymer nanoparticles for ovarian cancer chemotherapy.Journal of nanobiotechnology · 2022Article
- Injectable Thermosensitive Hydrogels for a Sustained Release of Iron Nanochelators.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2022Article
- Repurposing ICG enables MR/PA imaging signal amplification and iron depletion for iron-overload disorders.Science advances · 2021Article
- Chelators for Treatment of Iron and Copper Overload: Shift from Low-Molecular-Weight Compounds to Polymers.Polymers · 2021Review
- SARS-CoV-2 Mediated Hyperferritinemia and Cardiac Arrest: Preliminary Insights.Drug discovery today · 2021Review
- Article
- Towards Robust Delivery of Antimicrobial Peptides to Combat Bacterial Resistance.Molecules (Basel, Switzerland) · 2020Review
- Blood circulation of soft nanomaterials is governed by dynamic remodeling of protein opsonins at nano-biointerface.Nature communications · 2020Article
- Combating iron overload: a case for deferoxamine-based nanochelators.Nanomedicine (London, England) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic transfusion of red blood cells (RBCs) to patients with β-thalassemia, sickle cell disease, and other acquired anemic disorders generates significant amounts of bioactive iron deposits in the body. The inactivation and excretion of redox active iron(III) from the blood pool and organs are critical to prevent organ damage, and are the focus of iron chelation therapy (ICT) using low molecular weight Fe(III) specific chelators. However, the current ICT is suboptimal because of the short circulation time of chelators, toxicity, severe side effects, difficult regime of administration, and patient noncompliance. To address this issue, we have designed long circulating and biodegradable nanoconjugates with enhanced circulation time and well-defined biodegradability to improve iron excretion and avoid nonspecific organ accumulation. A series of iron chelating nanoconjugates were generated with deferoxamine (DFO) as the iron(III) specific chelator using polymer scaffolds containing structurally different acidic pH sensitive ketal groups. The type of degradation linkages used in the polymer scaffold significantly influenced the vascular residence time, biodistribution, and mode of excretion of chelators in mice. Remarkably, the conjugate, BGD-60 (140 kDa;
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.